(Q39345879)

11 September 2017

DNMT1: an emerging target in the treatment of invasive urinary bladder cancer (English)

1 reference

11 September 2017

8

Deborah W Knapp

1 reference

11 September 2017

Deepika Dhawan

1

1 reference

11 September 2017

José A Ramos-Vara

2

1 reference

11 September 2017

Noah M Hahn

3

1 reference

11 September 2017

Jolena Waddell

4

1 reference

11 September 2017

Gayla R Olbricht

5

1 reference

11 September 2017

Rong Zheng

6

1 reference

11 September 2017

Jane C Stewart

7

1 reference

11 September 2017

19 May 2012

1 reference

11 September 2017

1 reference

11 September 2017

31

1 reference

11 September 2017

1761-1769

1 reference

11 September 2017

8

1 reference

Effects of short-term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladder

11 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.03.015

DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.03.015

DNA methylation in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.03.015

Epigenetic therapy: histone acetylation, DNA methylation and anti-cancer drug discovery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.03.015

Epigenetics and cancer treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.03.015

Solving the Dnmt2 enigma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.03.015

Dnmt3a and Dnmt1 functionally cooperate during de novo methylation of DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.03.015

The de novo methylation activity of Dnmt3a is distinctly different than that of Dnmt1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.03.015

Review: recent clinical trials in epigenetic therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.03.015

DNA methyltransferase Dnmt1 associates with histone deacetylase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.03.015

CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.03.015

Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.03.015

DNA methylation of multiple tumor-related genes in association with overexpression of DNA methyltransferase 1 (DNMT1) during multistage carcinogenesis of the pancreas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.03.015

Histone deacetylase inhibitor Trichostatin A induces global and gene-specific DNA demethylation in human cancer cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.03.015

Coordinated changes in DNA methylation and histone modifications regulate silencing/derepression of luteinizing hormone receptor gene transcription

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.03.015

Inhibitors of histone deacetylase and DNA methyltransferase synergistically activate the methylated metallothionein I promoter by activating the transcription factor MTF-1 and forming an open chromatin structure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.03.015

Chromatin remodeling, histone modifications, and DNA methylation-how does it all fit together?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.03.015

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.03.015

Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.03.015

A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.03.015

Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.03.015

Subcutaneous 5-azacitidine treatment of naturally occurring canine urothelial carcinoma: a novel epigenetic approach to human urothelial carcinoma drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.03.015

The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.03.015

Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.03.015

Sensitization to gamma-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.03.015

Deacetylase inhibition in malignant melanomas: impact on cell cycle regulation and survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.03.015

Canine invasive transitional cell carcinoma cell lines: in vitro tools to complement a relevant animal model of invasive urinary bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.03.015

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.03.015

Epigenetic control of tumor suppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.03.015

Development of DNA methyltransferase inhibitors for the treatment of neoplastic diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.03.015

5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.03.015

What's taking so long? S-phase entry from quiescence versus proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.03.015

Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.03.015

Combined effects of retinoic acid and histone deacetylase inhibitors on human neuroblastoma SH-SY5Y cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.03.015

Cyclin D1 gene activation in human myeloma cells is independent of DNA hypomethylation or histone hyperacetylation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.03.015

Effect of trichostatin A on cell growth and expression of cell cycle- and apoptosis-related molecules in human gastric and oral carcinoma cell lines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.03.015

Tumor cell growth inhibition and cell differentiation analysis in a canine mammary tumor cell line (MCM-B2) treated with four chemical reagents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.03.015

Epigenetic modification regulates both expression of tumor-associated genes and cell cycle progressing in human colon cancer cell lines: Colo-320 and SW1116.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.03.015

10.1016/J.UROLONC.2012.03.015

7 January 2021

Identifiers

DOI

1 reference

11 September 2017

1 reference